Pharmaceuticals News and Research

RSS

Recent releases in Global Health

When health ministers gather for the World Health Assembly in May they will try to come up with a solution to "a dilemma that has dogged decision-makers for decades - whether and when to destroy the last remaining stocks of the smallpox virus," David Heymann and Emma Ross, both of the Global Health Security Centre at Chatham House, write in an article in The World Today.

25 Apr 2011

Molecular Templates to present preclinical data of ETB platform technology at 5th RNAi and miRNA World Congress

Molecular Templates, Inc., a biopharmaceutical company focused on the discovery and development of a new class of small biologic therapies called Engineered Toxin Bodies (ETB), announced today that it will present preclinical data in a poster presentation at the 5th Annual RNAi and miRNA World Congress in Boston, MA during April 26-27, 2011.

22 Apr 2011

Idera announces delay in commencement of IMO-2125 Phase 2 clinical trial in treatment-naive HCV patients

Idera Pharmaceuticals, Inc. today announced that it has chosen to delay initiating its planned Phase 2 clinical trial of IMO-2125 based on preliminary data from a 26-week nonclinical toxicology study of IMO-2125 in rodents. The Phase 2 clinical trial involves the evaluation of IMO-2125 plus ribavirin in treatment-naïve, genotype 1 hepatitis C virus (HCV) patients.

22 Apr 2011

Luitpold temporarily suspends distribution of drug products manufactured at Shirley, New York facility

Luitpold Pharmaceuticals, Inc. today announced that it has temporarily suspended distribution of all of its drug products manufactured at its Shirley, New York facility and marketed by its American Regent, Inc. subsidiary and Animal Health Division.

22 Apr 2011

Teva acknowledges promising results of DEFINE study in MS

We acknowledge the results of the DEFINE study seem promising for patients. It is important to note that as a general rule, results obtained in clinical trials in multiple sclerosis (MS) cannot be compared, unless agents are tested in a head-to-head manner in the same trial.

22 Apr 2011

BioCryst's BCX4208 study results in gout to be presented at EULAR meeting

BioCryst Pharmaceuticals, Inc. announced the presentation of clinical results related to BCX4208 for the treatment of gout at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism in London, England.

22 Apr 2011

Valeant issues statement to shareholders of Cephalon

Valeant Pharmaceuticals International, Inc. today issued the following statement to shareholders of Cephalon, Inc.

22 Apr 2011

United Water and NCPA embark on an effort to encourage safe disposal of unused medications

United Water and the National Community Pharmacists Association (NCPA) announced a partnership today to encourage people throughout the United States to properly dispose of their unused or expired medications in an environmentally-friendly manner. A major part of the campaign will center around the NCPA's website dedicated to the program - www.DisposeMyMeds.org - that directs people to their local independent pharmacy where they can drop off their unused medications.

22 Apr 2011

Hospitals to host Earth Day events emphasizing link between health, environment

Hospitals and other members of the health care sector will be marking Earth Day 2011 with a wide variety of events showcasing their efforts to develop sustainable operations and reduce their environmental footprint.

22 Apr 2011

Decision Resources: 63% of neurologists select Tysabri as effective MS treatment

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the majority of surveyed U.S. neurologists selected Biogen Idec/Elan's Tysabri as the most effective therapy for the treatment of relapsing-remitting multiple sclerosis, when compared to other currently available agents.

22 Apr 2011

Cephalon files definitive Consent Revocation Statement, recommends shareholders to reject Valeant's proposals

Cephalon, Inc. today announced that it has filed a definitive Consent Revocation Statement with the Securities and Exchange Commission (SEC) urging shareholders to reject Valeant Pharmaceuticals International Inc.'s proposals to remove Cephalon's entire Board of Directors and replace them with nominees hand-picked by Valeant.

22 Apr 2011

Velos and Comaiba collaborate to provide healthcare risk and compliance management solutions

Velos, Inc., the trusted leader in clinical trial management systems for large academic medical centers and research institutions, today announced an initiative to provide solutions for customers in the areas of risk management and compliance monitoring in research, transplant medicine, and biospecimen management.

22 Apr 2011

NPR: 3 in 4 prescriptions are for generic drugs

The brand-name pharmaceutical industry has a drug problem. All 10 of the most prescribed medicines in the U.S. last year were generics, led by the defending champion generic equivalents of Vicodin.

22 Apr 2011

Fleming ramps up production of ThyroShield to meet increased domestic and international demand

Fleming Pharmaceuticals, maker of ThyroShield– the only FDA approved liquid potassium iodide product indicated for thyroid protection in radiation emergencies – announced today that it has implemented the changes necessary to ramp up production to meet increased domestic and international demand.

22 Apr 2011

Researchers discover new compound to fight against shingles

Researchers at the University of Georgia and Yale University have discovered a compound with the potential to be more effective than existing agents in treating the very painful blisters known as shingles-a condition that affects up to 30 percent of Americans, mostly elderly, and for which no specific treatment exists.

22 Apr 2011

FDA approves Spectrum's FUSILEV Injection to treat metastatic colorectal cancer

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that the U.S. Food and Drug Administration has approved the Company's Supplemental New Drug Application for FUSILEV Injection.

22 Apr 2011

Marinus initiates ganaxolone Phase 2 trial in posttraumatic stress disorder

Marinus Pharmaceuticals, Inc., the leader in the development of neurosteroids for central nervous system disorders, today announced commencement of a proof-of-concept clinical trial of its lead candidate ganaxolone for the treatment of posttraumatic stress disorder.

22 Apr 2011

Convergence initiates CNV2197944 Phase I study in chronic pain

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines, today announced that the first-time-in-man Phase I study of the novel, first in class calcium channel blocker CNV2197944, for the treatment of chronic pain has been initiated and dosing has begun.

22 Apr 2011

UC Berkeley researchers form new Synthetic Biology Institute

An alliance of top researchers at the University of California, Berkeley, has formed the UC Berkeley Synthetic Biology Institute, advancing efforts to engineer cells and biological systems in ways that promise to transform technology in health and medicine, energy, the environment, new materials, and a host of other critical arenas.

22 Apr 2011

USPTO issues patent to Oragenics ProBiora3 for oral care

Florida-based biopharmaceutical company Oragenics, Inc. announced today the issuance of patent number 7931892 from the United States Patent and Trademark office for ProBiora3, a proprietary blend of naturally occurring oral bacteria shown to produce a wide range of oral care benefits.

22 Apr 2011

Pharmaceuticals News and Research

Recent releases in Global Health

Molecular Templates to present preclinical data of ETB platform technology at 5th RNAi and miRNA World Congress

Idera announces delay in commencement of IMO-2125 Phase 2 clinical trial in treatment-naive HCV patients

Luitpold temporarily suspends distribution of drug products manufactured at Shirley, New York facility

Teva acknowledges promising results of DEFINE study in MS

BioCryst's BCX4208 study results in gout to be presented at EULAR meeting

Valeant issues statement to shareholders of Cephalon

United Water and NCPA embark on an effort to encourage safe disposal of unused medications

Hospitals to host Earth Day events emphasizing link between health, environment

Decision Resources: 63% of neurologists select Tysabri as effective MS treatment

Cephalon files definitive Consent Revocation Statement, recommends shareholders to reject Valeant's proposals

Velos and Comaiba collaborate to provide healthcare risk and compliance management solutions

NPR: 3 in 4 prescriptions are for generic drugs

Fleming ramps up production of ThyroShield to meet increased domestic and international demand

Researchers discover new compound to fight against shingles

FDA approves Spectrum's FUSILEV Injection to treat metastatic colorectal cancer

Marinus initiates ganaxolone Phase 2 trial in posttraumatic stress disorder

Convergence initiates CNV2197944 Phase I study in chronic pain

UC Berkeley researchers form new Synthetic Biology Institute

USPTO issues patent to Oragenics ProBiora3 for oral care

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence